These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24282029)

  • 21. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
    Johansson I; Ingelman-Sundberg M
    Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of neutral and deleterious protein-coding variation among individuals and populations.
    Fu W; Gittelman RM; Bamshad MJ; Akey JM
    Am J Hum Genet; 2014 Oct; 95(4):421-36. PubMed ID: 25279984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
    Daily EB; Aquilante CL
    Pharmacogenomics; 2009 Sep; 10(9):1489-510. PubMed ID: 19761371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations.
    Matura JM; Shea LA; Bankes VA
    Ir J Med Sci; 2022 Oct; 191(5):2357-2365. PubMed ID: 34734388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic implications of polymorphisms in cytochromes and drug transporters].
    Münster E; Ziegler S; Brunner M
    Wien Med Wochenschr; 2005 Feb; 155(3-4):54-8. PubMed ID: 15791777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations for rare variants in drug metabolism genes and the clinical implications.
    Drögemöller BI; Wright GE; Warnich L
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):873-84. PubMed ID: 24673405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
    Ingelman-Sundberg M
    Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.
    Gaedigk A; Ingelman-Sundberg M; Miller NA; Leeder JS; Whirl-Carrillo M; Klein TE;
    Clin Pharmacol Ther; 2018 Mar; 103(3):399-401. PubMed ID: 29134625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database.
    Sim SC; Ingelman-Sundberg M
    Methods Mol Biol; 2013; 987():251-9. PubMed ID: 23475683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.
    Morrison A; Levy R
    Pharmacogenomics; 2004 Sep; 5(6):673-89. PubMed ID: 15335288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing.
    Hocum BT; White JR; Heck JW; Thirumaran RK; Moyer N; Newman R; Ashcraft K
    Am J Health Syst Pharm; 2016 Jan; 73(2):61-7. PubMed ID: 26721535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canine cytochrome P-450 pharmacogenetics.
    Court MH
    Vet Clin North Am Small Anim Pract; 2013 Sep; 43(5):1027-38. PubMed ID: 23890236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes.
    Fukunaga K; Momozawa Y; Mushiroda T
    Drug Metab Pharmacokinet; 2021 Apr; 37():100370. PubMed ID: 33508759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
    Yokoi T; Kamataki T
    Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic insight into cytochrome P450 in Chinese from the Chinese Millionome Database.
    Qi G; Han C; Sun Y; Zhou Y
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):341-352. PubMed ID: 31661191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.